Long COVID Trial, Recruiting NCT07374562 Sponsor: Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec Condition: Long COVID
Back to Long Covid

Long COVID Trial, Recruiting

NCT07374562
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You either had a confirmed positive COVID-19 test (any type) at least 3 months before joining the trial, OR a doctor at the trial site believes you had COVID-19 based on your symptoms after October 15, 2019, even without a positive test
  • You have had ongoing symptoms for at least 12 weeks (and at least 2 months) since your COVID-19 illness began
  • Your ability to carry out daily activities has been noticeably affected by your ongoing symptoms, as measured by a specific scale (confirm with trial site)
  • You still have ongoing shortness of breath that is at least moderate in severity, at least 12 weeks after your COVID-19 infection
  • You are still experiencing COVID-19-related symptoms at the time you join the trial
  • If you are taking any medications for tiredness or memory/thinking problems, you have been on a stable dose of those medications for at least 4 weeks before joining, and you are willing to try to keep them the same during the study
  • You are able and willing to sign a consent form agreeing to take part
  • You are able to read and understand French

Who may not be able to join:

  • You have previously been diagnosed with myalgic encephalomyelitis (ME) or fibromyalgia
  • You were already on sick leave or receiving disability benefits at the time you first got COVID-19
  • You are currently pregnant or breastfeeding
  • You have had a heart attack within the last 12 weeks
  • You are currently taking blood-thinning medications
  • You have been diagnosed with glaucoma (a condition affecting eye pressure)
  • You have severe emphysema that requires you to use oxygen at home
  • You have a known problem with your heart's electrical system that affects its rhythm (confirm with trial site)
  • You have a known allergy or sensitivity to a medication called bupivacaine
  • You have previously had a procedure called a stellate ganglion block
  • The trial doctor decides, for any medical reason, that the treatment being studied is not appropriate for you

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 819 697-3333

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec
Registry
ClinicalTrials.gov
Start date
5 February 2026
Est. completion
1 February 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Post-COVID-19 Functional Status Scale (PCFS); Fatigue Severity Scale (FSS); Brain Fog Scale (BFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov